Potassium-chloride cotransporter type 2 (KCC2)

Potassium-chloride cotransporter type 2 (KCC2) is a neuron-specific membrane transporter encoded by the SLC12A5 gene that extrudes chloride ions from neurons in exchange for potassium, maintaining a low intracellular chloride concentration essential for effective synaptic inhibition by GABA and glycine[8][9][1][5]. KCC2 plays a critical role in regulating neuronal excitability, the GABAergic "inhibitory switch" during brain maturation, and overall central nervous system chloride homeostasis. Dysfunction or decreased expression of KCC2 is implicated in a variety of neurological disorders, including epilepsy, neuropathic pain, spasticity, and some neurodegenerative and traumatic CNS conditions[1][2][5][8][9]. KCC2 is considered a promising therapeutic target for restoring inhibitory tone in CNS disorders, and several drug candidates (e.g., CLP257, CLP290) are in advanced preclinical development to activate or potentiate its function, though no such therapies are approved yet. Existing clinical agents such as furosemide and VU0240511 can inhibit KCC2 but lack selectivity and clinical utility for CNS indications[6]. Select biomarkers for KCC2 dysfunction include reduced transporter expression in patient brain samples and animal models. Safety concerns for future therapeutics center on CNS selectivity and the risk of distorting inhibitory/excitatory balance with excessive modulation.

Other names

KCC2SLC12A5neuron-specific potassium-chloride cotransporterpotassium-chloride cotransporter-2potassium chloride cotransporter 2

KCC2 functional enhancers increase chloride extrusion and restore inhibitory GABA/glycine signaling (e.g., CLP257, CLP290)[3] Indirect pharmacological upregulation (via 5-HT2A receptor activation, e.g., TCB-2)[2] Inhibitors block transporter function, raising neuronal chloride concentration (rarely the therapeutic goal)[6]